HIV diagnostics: Challenges and opportunities

HIV Therapy

Volumn 4, Issue 4, 2010, Pages 399-412

  Wong, Eric Y ^a   Hewlett, Indira K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

biodetection; diagnostic; drug resistance; HIV; rapid test

Indexed keywords

INTEGRASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOSIDE; PROTEIN INHIBITOR;

CD4 LYMPHOCYTE COUNT; DISEASE TRANSMISSION; GENETIC VARIABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOASSAY; MIXED INFECTION; MORBIDITY; ORGAN TRANSPLANTATION; REVIEW; TISSUE TRANSPLANTATION; VIRUS LOAD; VIRUS RESISTANCE; VIRUS STRAIN;

EID: 77957935148     PISSN: 17584310     EISSN: None     Source Type: Journal    
DOI: 10.2217/hiv.10.29     Document Type: Review

References (155)

1. Calmy A, Ford N, Hirschel B et al.: HIV viral load monitoring in resource-limited regions: optional or necessary? Clin. Infect. Dis. 44, 128-134 (2007). (Pubitemid 44968997)
2. Prendergast A, Tudor-Williams G, Jeena P, Burchett S, Goulder P: International perspectives, progress, and future challenges of paediatric HIV infection. Lancet 370, 68-80 (2007). (Pubitemid 47018314)
3. Cohen MS, Hellmann N, Levy JA, DeCock K, Lange J: The spread, treatment, and prevention of HIV-1: evolution of a global pandemic. J. Clin. Invest. 118, 1244-1254 (2008).
4. Klausner JD, Wamai RG, Bowa K, Agot K, Kagimba J, Halperin DT: Is male circumcision as good as the HIV vaccine we've been waiting for? Future HIV Ther. 2(1), 1-7 (2008).
5. Simon V, Ho DD, Abdool Karim Q: HIV/ AIDS epidemiology, pathogenesis, prevention, and treatment. Lancet 368, 489-504 (2006).
6. Weiss HA, Halperin D, Bailey RC, Hayes RJ, Schmid G, Hankins CA: Male circumcision for HIV prevention: from evidence to action? AIDS 22, 567-574 (2008).
7. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A: Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2, e298 (2005).
8. Bailey RC, Moses S, Parker CB et al.: Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 369, 643-656 (2007). (Pubitemid 46281312)
9. Gray RH, Kigozi G, Serwadda D et al.: Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 369, 657-666 (2007).
10. Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217-223.
11. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al.: Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
12. Cutler B, Justman J: Vaginal microbicides and the prevention of HIV transmission. Lancet Infect. Dis. 8, 685-697 (2008).
13. Grant RM, Hamer D, Hope T et al.: Whither or wither microbicides? Science 321, 532-534 (2008).
14. Pantaleo G: HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect. Dis. 8, 82-83 (2008).
15. Pantophlet R, Burton DR: GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739-769 (2006).
16. Desrosiers RC: Prospects for an AIDS vaccine. Nat. Med. 10, 221-223 (2004).
17. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr: Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 372, 585-599 (2008).
18. Cohen MS, Kashuba AD: Antiretroviral therapy for prevention of HIV infection: new clues from an animal model. PLoS Med. 5, e30 (2008).
19. Willyard C: A preemptive strike against HIV. Nat. Med. 15, 126-129 (2009).
20. Abdool Karim SS, Baxter C: Antiretroviral prophylaxis for the prevention of HIV infection: future implementation and challenges. HIV Ther. 3(1), 3-6 (2009).
21. Rotheram-Borus MJ, Swendeman D, Chovnick G: The past, present, and future of HIV prevention: integrating behavioral, biomedical, and structural intervention strategies for the next generation of HIV prevention. Annu. Rev. Clin. Psychol. 5, 143-167 (2009).
22. Wainberg MA, Jeang KT: 25 years of HIV-1 research - progress and perspectives. BMC Med. 6, 31 (2008).
23. Hammer SM, Eron JJ Jr, Reiss P et al.: Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 300, 555-570 (2008).
24. Dieffenbach CW, Fauci AS: Universal voluntary testing and treatment for prevention of HIV transmission. JAMA 301, 2380-2382 (2009).
25. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG: Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 373, 48-57 (2009).
26. Stramer SL, Glynn SA, Kleinman SH et al.: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N. Engl. J. Med. 351, 760-768 (2004).
27. Pandori MW, Hackett J Jr, Louie B et al.: Assessment of the ability of a fourthgeneration immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting. J. Clin. Microbiol. 47, 2639-2642 (2009).
28. Stevens W, Sherman G, Downing R et al.: Role of the laboratory in ensuring global access to ARV treatment for HIV-infected children: consensus statement on the performance of laboratory assays for early infant diagnosis. Open AIDS J. 2, 17-25 (2008).
29. Uttayamakul S, Likanonsakul S, Sunthornkachit R et al.: Usage of dried blood spots for molecular diagnosis and monitoring HIV-1 infection. J. Virol. Methods 128, 128-134 (2005).
30. Yager P, Domingo GJ, Gerdes J: Point-of-care diagnostics for global health. Annu. Rev. Biomed. Eng. 10, 107-144 (2008). ■■ Provides excellent descriptions of the diagnostic tools currently employed.
31. Okie S: Global health - the Gates-Buffett effect. N. Engl. J. Med. 355, 1084-1088 (2006).
32. Gilks CF, Crowley S, Ekpini R et al.: The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 368, 505-510 (2006). (Pubitemid 44142772)
33. Chin CD, Linder V, Sia SK: Lab-on-a-chip devices for global health: past studies and future opportunities. Lab Chip 7, 41-57 (2007).
34. Plate DK: Evaluation and implementation of rapid HIV tests: the experience in 11 African countries. AIDS Res. Hum. Retroviruses 23, 1491-1498 (2007).
35. Allain JP, Lee H: Rapid tests for detection of viral markers in blood transfusion. Expert Rev. Mol. Diagn. 5, 31-41 (2005).
36. Cheng MM, Cuda G, Bunimovich YL et al.: Nanotechnologies for biomolecular detection and medical diagnostics. Curr. Opin. Chem. Biol. 10, 11-19 (2006).
37. Yager P, Edwards T, Fu E et al.: Microfluidic diagnostic technologies for global public health. Nature 442, 412-418 (2006). (Pubitemid 44264785)
38. Chappel RJ, Wilson KM, Dax EM: Immunoassays for the diagnosis of HIV: meeting future needs by enhancing the quality of testing. Future Microbiol. 4, 963-982 (2009).
39. Gray RH, Makumbi F, Serwadda D et al.: Limitations of rapid HIV-1 tests during screening for trials in Uganda: diagnostic test accuracy study. BMJ 335, 188 (2007).
40. Brennan CA, Bodelle P, Coffey R et al.: HIV global surveillance: foundation for retroviral discovery and assay development. J. Med. Virol. 78(Suppl. 1), S24-S29 (2006).
41. Cachafeiro A, Sherman GG, Sohn AH, Beck-Sague C, Fiscus SA: Diagnosis of human immunodeficiency virus type 1 infection in infants by use of dried blood spots and an ultrasensitive p24 antigen assay. J. Clin. Microbiol. 47, 459-462 (2009).
42. Chaillet P, Zachariah R, Harries K, Rusanganwa E, Harries AD: Dried blood spots are a useful tool for quality assurance of rapid HIV testing in Kigali, Rwanda. Trans. R. Soc. Trop. Med. Hyg. (2009) (Epub ahead of print).
43. Ou CY, Yang H, Balinandi S et al.: Identification of HIV-1 infected infants and young children using real-time RT PCR and dried blood spots from Uganda and Cameroon. J. Virol. Methods 144, 109-114 (2007). (Pubitemid 47103223)
44. Havens PL, Mofenson LM: Evaluation and management of the infant exposed to HIV-1 in the United States. Pediatrics 123, 175-187 (2009).
45. Taha TE, Hoover DR, Kumwenda NI et al.: Late postnatal transmission of HIV-1 and associated factors. J. Infect. Dis. 196, 10-14 (2007).
46. Schupbach J: Viral RNA and p24 antigen as markers of HIV disease and antiretroviral treatment success. Int. Arch. Allergy Immunol. 132, 196-209 (2003).
47. Busch MP, Satten GA: Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am. J. Med. 102, 117-124; discussion 125-126 (1997).
48. Le Vu S, Pillonel J, Semaille C et al.: Principles and uses of HIV incidence estimation from recent infection testing - a review. Euro Surveill. 13(36), 18969 (2008).
49. Hargrove JW, Humphrey JH, Mutasa K et al.: Improved HIV-1 incidence estimates using the BED capture enzyme immunoassay. AIDS 22, 511-518 (2008).
50. McDougal JS, Parekh BS, Peterson ML et al.: Comparison of HIV type 1 incidence observed during longitudinal follow-up with incidence estimated by cross-sectional ana lysis using the BED capture enzyme immunoassay. AIDS Res. Hum. Retroviruses 22, 945-952 (2006).
51. Chawla A, Murphy G, Donnelly C et al.: Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J. Clin. Microbiol. 45, 415-420 (2007). (Pubitemid 46272055)
52. Barin F, Meyer L, Lancar R et al.: Development and validation of an immunoassay for identification of recent human immunodeficiency virus type 1 infections and its use on dried serum spots. J. Clin. Microbiol. 43, 4441-4447 (2005). (Pubitemid 41298225)
53. Murphy G, Parry JV: Assays for the detection of recent infections with human immunodeficiency virus type 1. Euro Surveill. 13 (2008).
54. Guy R, Gold J, Calleja JM et al.: Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review. Lancet Infect. Dis. 9, 747-759 (2009).
55. Sakarovitch C, Rouet F, Murphy G et al.: Do tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa? J. Acquir. Immune Defic. Syndr. 45, 115-122 (2007).
56. Ayers LW, Silver S, McGrath MS, Orenstein JM: The AIDS and cancer specimen resource: role in HIV/AIDS scientific discovery. Infect. Agent Cancer 2, 7 (2007).
57. Busch MP, Glynn SA: Use of blood-donor and transfusion-recipient biospecimen repositories to address emerging blood-safety concerns and advance infectious disease research: the National Heart, Lung, and Blood Institute Biologic Specimen Repository. J. Infect. Dis. 199, 1564-1566 (2009).
58. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM: The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358, 1590-1602 (2008). ■■ Excellent article describing global epidemiology of HIV.
59. Ndongmo CB, Pieniazek D, Holberg- Petersen M et al.: HIV genetic diversity in Cameroon: possible public health importance. AIDS Res. Hum. Retroviruses 22, 812-816 (2006). (Pubitemid 44735010)
60. Aghokeng AF, Mpoudi-Ngole E, Dimodi H et al.: Inaccurate diagnosis of HIV-1 group M and O is a key challenge for ongoing universal access to antiretroviral treatment and HIV prevention in Cameroon. PLoS ONE 4, e7702 (2009).
61. Lee S, Wood O, Tang S et al.: Detection of emerging HIV variants in blood donors from urban areas of Cameroon. AIDS Res. Hum. Retroviruses 23, 1262-1267 (2007).
62. McShane H: Co-infection with HIV and TB: double trouble. Int. J. STD AIDS 16, 95-100; quiz 101 (2005).
63. Singh JA, Upshur R, Padayatchi N: XDR-TB in South Africa: no time for denial or complacency. PLoS Med. 4, e50 (2007).
64. Abu-Raddad LJ, Patnaik P, Kublin JG: Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. Science 314, 1603-1606 (2006). (Pubitemid 44907155)
65. Levy V, Grant RM: Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls. Clin. Infect. Dis. 43, 904-910 (2006).
66. Soriano V, Puoti M, Sulkowski M et al.: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 21, 1073-1089 (2007).
67. Kublin JG, Patnaik P, Jere CS et al.: Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 365, 233-240 (2005). (Pubitemid 40138017)
68. Laufer MK, van Oosterhout JJ, Thesing PC et al.: Impact of HIV-associated immunosuppression on malaria infection and disease in Malawi. J. Infect. Dis. 193, 872-878 (2006).
69. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S: Survival rate and risk factors of mortality among HIV/ tuberculosis-coinfected patients with and without antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 43, 42-46 (2006). (Pubitemid 44306486)
70. Syre H, Myneedu VP, Arora VK, Grewal HM: Direct detection of mycobacterial species in pulmonary specimens by two rapid amplification tests, the gen-probe amplified Mycobacterium tuberculosis direct test and the genotype mycobacteria direct test. J. Clin. Microbiol. 47, 3635-3639 (2009).
71. Pai M, Ling DI: Rapid diagnosis of extrapulmonary tuberculosis using nucleic acid amplification tests: what is the evidence? Future Microbiol. 3, 1-4 (2008).
72. Khurana S, Needham J, Mathieson B et al.: Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies. J. Virol. 80, 2092-2099 (2006).
73. Khurana S, Needham J, Park S et al.: Novel approach for differential diagnosis of HIV infections in the face of vaccine-generated antibodies: utility for detection of diverse HIV-1 subtypes. J. Acquir. Immune Defic. Syndr. 43, 304-312 (2006).
74. Khurana S, Norris PJ, Busch MP et al.: HIV-Selectest enzyme immunoassay and rapid test: ability to detect seroconversion following HIV-1 infection. J. Clin. Microbiol. 48, 281-285 (2010).
75. Ahn J, Cohen SM: Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transpl. 14, 1603-1608 (2008).
76. Fishman JA, Greenwald MA, Kuehnert MJ: Enhancing transplant safety: a new era in the microbiologic evaluation of organ donors? Am. J. Transplant. 7, 2652-2654 (2007).
77. Tang S, Moayeri M, Chen Z et al.: Detection of anthrax toxin by an ultrasensitive immunoassay using europium nanoparticles. Clin. Vaccine Immunol. 16, 408-413 (2009).
78. Tang S, Zhao J, Storhoff JJ et al.: Nanoparticle-based biobarcode amplification assay (BCA) for sensitive and early detection of human immunodeficiency type 1 capsid (p24) antigen. J. Acquir. Immune Defic. Syndr. 46, 231-237 (2007). (Pubitemid 47482620)
79. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF: The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir. Ther. 13(Suppl. 2), 1-13 (2008). (Pubitemid 352019085)
80. Hirsch MS, Gunthard HF, Schapiro JM et al.: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin. Infect. Dis. 47, 266-285 (2008).
81. Colson P, Solas C, Moreau J, Motte A, Henry M, Tamalet C: Impaired quantification of plasma HIV-1 RNA with a commercialized real-time PCR assay in a couple of HIV-1-infected individuals. J. Clin. Virol. 39, 226-229 (2007).
82. Kiwanuka N, Laeyendecker O, Robb M et al.: Effect of human immunodeficiency virus type 1 (HIV-1) subtype on disease progression in persons from Rakai, Uganda, with incident HIV-1 infection. J. Infect. Dis. 197, 707-713 (2008).
83. Yao JD, Germer JJ, Damond F, Roquebert B, Descamps D: Plasma load discrepancies between the Roche Cobas Amplicor human immunodeficiency virus type 1 (HIV-1) Monitor version 1.5 and Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assays. J. Clin. Microbiol. 46, 834; author reply 834 (2008).
84. Clavel F, Hance AJ: HIV drug resistance. N. Engl. J. Med. 350, 1023-1035 (2004). (Pubitemid 38269279)
85. Check E: AIDS treatment: staying the course. Nature 442, 617-619 (2006).
86. Vasan A, Hoos D, Mukherjee JS, Farmer PE, Rosenfield AG, Perriens JH: The pricing and procurement of antiretroviral drugs: an observational study of data from the Global Fund. Bull. World Health Organ. 84, 393-398 (2006).
87. Koyalta D, Charpentier C, Beassamda J et al.: High frequency of antiretroviral drug resistance among HIV-infected adults receiving first-line highly active antiretroviral therapy in N'Djamena, Chad. Clin. Infect. Dis. 49, 155-159 (2009).
88. Ekouevi DK, Tonwe-Gold B, Dabis F: Advances in the prevention of mother-tochild transmission of HIV-1 infection in resource-limited settings. AIDS Read. 15, 479-480, 487-493 (2005).
89. Johnson JA, Li JF, Morris L et al.: Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J. Infect. Dis. 192, 16-23 (2005).
90. Lockman S, Shapiro RL, Smeaton LM et al.: Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N. Engl. J. Med. 356, 135-147 (2007). (Pubitemid 46089674)
91. Weinstock HS, Zaidi I, Heneine W et al.: The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J. Infect. Dis. 189, 2174-2180 (2004). (Pubitemid 38757188)
92. Booth CL, Geretti AM: Prevalence and determinants of transmitted antiretroviral drug resistance in HIV-1 infection. J. Antimicrob. Chemother. 59, 1047-1056 (2007).
93. Halvas EK, Aldrovandi GM, Balfe P et al.: Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency. J. Clin. Microbiol. 44, 2612-2614 (2006).
94. Bushman FD, Hoffmann C, Ronen K et al.: Massively parallel pyrosequencing in HIV research. AIDS 22, 1411-1415 (2008).
95. Mardis ER: The impact of next-generation sequencing technology on genetics. Trends Genet. 24, 133-141 (2008).
96. Tsibris AM, Korber B, Arnaout R et al.: Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS ONE 4, e5683 (2009).
97. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW: Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res. 17, 1195-1201 (2007).
98. Simen BB, Simons JF, Hullsiek KH et al.: Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J. Infect. Dis. 199, 693-701 (2009).
99. Shendure J, Ji H: Next-generation DNA sequencing. Nat. Biotechnol. 26, 1135-1145 (2008).
100. Cordes F, Kaiser R, Selbig J: Bioinformatics approach to predicting HIV drug resistance. Expert Rev. Mol. Diagn. 6, 207-215 (2006). (Pubitemid 44167149)
101. Lengauer T, Sander O, Sierra S, Thielen A, Kaiser R: Bioinformatics prediction of HIV coreceptor usage. Nat. Biotechnol. 25, 1407-1410 (2007). (Pubitemid 350233143)
102. Rose JD, Rhea AM, Weber J, Quinones-Mateu ME: Current tests to evaluate HIV-1 coreceptor tropism. Curr. Opin. HIV AIDS 4, 136-142 (2009).
103. Gazzard B, Bernard AJ, Boffito M et al.: British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 7, 487-503 (2006).
104. Hammer SM, Saag MS, Schechter M et al.: Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 296, 827-843 (2006).
105. Jennings C, Fiscus SA, Crowe SM et al.: Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J. Clin. Microbiol. 43, 5950-5956 (2005). (Pubitemid 43100643)
106. Rouet F, Ekouevi DK, Chaix ML et al.: Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J. Clin. Microbiol. 43, 2709-2717 (2005). (Pubitemid 40827943)
107. Dineva MA, MahiLum-Tapay L, Lee H: Sample preparation: a challenge in the development of point-of-care nucleic acid-based assays for resource-limited settings. Analyst 132, 1193-1199 (2007).
108. Glencross DK, Janossy G, Coetzee LM et al.: Large-scale affordable PanLeucogated CD4+ testing with proactive internal and external quality assessment: in support of the South African national comprehensive care, treatment and management programme for HIV and AIDS. Cytometry B Clin. Cytom. 74(Suppl. 1), S40-S51 (2008).
109. Hoffman J, van Griensven J, Colebunders R, McKellar M: Role of the CD4 count in HIV management. HIV Ther. 4(1), 27-39 (2010).
110. Haber C: Microfluidics in commercial applications; an industry perspective. Lab Chip 6, 1118-1121 (2006).
111. Martinez AW, Phillips ST, Whitesides GM: Three-dimensional microfluidic devices fabricated in layered paper and tape. Proc. Natl Acad. Sci. USA 105, 19606-19611 (2008).
112. Whitesides GM: The origins and the future of microfluidics. Nature 442, 368-373 (2006).
113. Auroux PA, Koc Y, deMello A, Manz A, Day PJ: Miniaturised nucleic acid ana lysis. Lab Chip 4, 534-546 (2004).
114. Zhang C, Xing D: Miniaturized PCR chips for nucleic acid amplification and ana lysis: latest advances and future trends. Nucleic Acids Res. 35, 4223-4237 (2007).
115. + T cell counting of HIV-infected subjects. Lab Chip 7, 170-178 (2007).
116. Cheng X, Liu YS, Irimia D et al.: Cell detection and counting through cell lysate impedance spectroscopy in microfluidic devices. Lab Chip 7, 746-755 (2007).
117. DeVoe DL, Lee CS: Microfluidic technologies for MALDI-MS in proteomics. Electrophoresis 27, 3559-3568 (2006).
118. Kling J: Moving diagnostics from the bench to the bedside. Nat. Biotechnol. 24, 891-893 (2006).
119. Koster S, Verpoorte E: A decade of microfluidic ana lysis coupled with electrospray mass spectrometry: an overview. Lab Chip 7, 1394-1412 (2007). (Pubitemid 350013203)
120. Myers FB, Lee LP: Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab Chip 8, 2015-2031 (2008).
121. Pal R, Yang M, Lin R et al.: An integrated microfluidic device for influenza and other genetic analyses. Lab Chip 5, 1024-1032 (2005).
122. Yang S, Liu J, Lee CS, Devoe DL: Microfluidic 2-D PAGE using multifunctional in situ polyacrylamide gels and discontinuous buffers. Lab Chip 9, 592-599 (2009).
123. + T-cell monitoring in the context of scaling-up antiretroviral treatment at the district level in Malawi. Trans. R. Soc. Trop. Med. Hyg. 100, 980-985 (2006).
124. Rodriguez WR, Christodoulides N, Floriano PN et al.: A microchip CD4 counting method for HIV monitoring in resource-poor settings. PLoS Med. 2, e182 (2005).
125. Spacek LA, Shihab HM, Lutwama F et al.: Evaluation of a low-cost method, the Guava EasyCD4 assay, to enumerate CD4-positive lymphocyte counts in HIV-infected patients in the United States and Uganda. J. Acquir. Immune Defic. Syndr. 41, 607-610 (2006). (Pubitemid 43756142)
126. Martinez AW, Phillips ST, Carrilho E, Thomas SW 3rd, Sindi H, Whitesides GM: Simple telemedicine for developing regions: camera phones and paper-based microfluidic devices for real-time, off-site diagnosis. Anal. Chem. 80, 3699-3707 (2008). (Pubitemid 351705870)
127. Patolsky F, Zheng G, Lieber CM: Nanowire sensors for medicine and the life sciences. Nanomedicine (Lond.) 1, 51-65 (2006).
128. Patolsky F, Zheng G, Hayden O, Lakadamyali M, Zhuang X, Lieber CM: Electrical detection of single viruses. Proc. Natl Acad. Sci. USA 101, 14017-14022 (2004). (Pubitemid 39305021)
129. Baller MK, Fritz J: Nanomechanical cantilever sensors for microarrays. In: Protein Microarray Technology. Kambhampati D (Ed.). Wiley-VCH Publisher, Weinheim, Germany, 195-213 (2004).
130. Fritz J, Baller MK, Lang HP et al.: Translating biomolecular recognition into nanomechanics. Science 288, 316-318 (2000).
131. Shu W, Laurenson S, Knowles TP, Ko Ferrigno P, Seshia AA: Highly specific label-free protein detection from lysed cells using internally referenced microcantilever sensors. Biosens. Bioelectron. 24, 233-237 (2008).
132. Hedstrom M, Galaev IY, Mattiasson B: Continuous measurements of a binding reaction using a capacitive biosensor. Biosens. Bioelectron. 21, 41-48 (2005).
133. Labib M, Hedstrom M, Amin M, Mattiasson B: A novel competitive capacitive glucose biosensor based on concanavalin A-labeled nanogold colloids assembled on a polytyramine-modified gold electrode. Anal. Chim. Acta 659, 194-200 (2010).
134. Labib M, Hedstrom M, Amin M, Mattiasson B: A capacitive immunosensor for detection of cholera toxin. Anal. Chim. Acta 634, 255-261 (2009).
135. Labib M, Hedstrom M, Amin M, Mattiasson B: A capacitive biosensor for detection of staphylococcal enterotoxin B. Anal. Bioanal. Chem. 393, 1539-1544 (2009).
136. Labib M, Hedstrom M, Amin M, Mattiasson B: A multipurpose capacitive biosensor for assay and quality control of human immunoglobulin G. Biotechnol. Bioeng. 104, 312-320 (2009).
137. Loyprasert S, Hedstrom M, Thavarungkul P, Kanatharana P, Mattiasson B: Sub-attomolar detection of cholera toxin using a label-free capacitive immunosensor. Biosens. Bioelectron. 25, 1977-1983 (2010).
138. Shim SY, Lim DK, Nam JM: Ultrasensitive optical biodiagnostic methods using metallic nanoparticles. Nanomedicine (Lond.) 3, 215-232 (2008).
139. Rosi NL, Mirkin CA: Nanostructures in biodiagnostics. Chem. Rev. 105, 1547-1562 (2005).
140. Angenendt P: Progress in protein and antibody microarray technology. Drug Discov. Today 10, 503-511 (2005).
141. Bertone P, Snyder M: Advances in functional protein microarray technology. FEBS J. 272, 5400-5411 (2005). (Pubitemid 41579404)
142. Gosalia DN, Salisbury CM, Maly DJ, Ellman JA, Diamond SL: Profiling serine protease substrate specificity with solution phase fluorogenic peptide microarrays. Proteomics 5, 1292-1298 (2005).
143. Gresham D, Ruderfer DM, Pratt SC et al.: Genome-wide detection of polymorphisms at nucleotide resolution with a single DNA microarray. Science 311, 1932-1936 (2006).
144. Uttamchandani M, Yao SQ: Peptide microarrays: next generation biochips for detection, diagnostics and high-throughput screening. Curr. Pharm. Des. 14, 2428-2438 (2008).
145. Wong EY, Diamond SL: Enzyme microarrays assembled by acoustic dispensing technology. Anal. Biochem. 381, 101-106 (2008).
146. Wong EY, Diamond SL: Advancing microarray assembly with acoustic dispensing technology. Anal. Chem. 81, 509-514 (2009).
147. Uttamchandani M, Neo JL, Ong BN, Moochhala S: Applications of microarrays in pathogen detection and biodefence. Trends Biotechnol. 27, 53-61 (2009).
148. Berensmeier S: Magnetic particles for the separation and purification of nucleic acids. Appl. Microbiol. Biotechnol. 73, 495-504 (2006).
149. Lien KY, Lin JL, Liu CY, Lei HY, Lee GB: Purification and enrichment of virus samples utilizing magnetic beads on a microfluidic system. Lab Chip 7, 868-875 (2007).
150. Bunka DH, Stockley PG: Aptamers come of age - at last. Nat. Rev. Microbiol. 4, 588-596 (2006).
151. Javaherian S, Musheev MU, Kanoatov M, Berezovski MV, Krylov SN: Selection of aptamers for a protein target in cell lysate and their application to protein purification. Nucleic Acids Res. 37, e62 (2009).
152. Joint United Nations Programme on HIV/AIDS: 2008 Report on the global AIDS epidemic www.unaids.org/en/ ■■ A great reference for the global epidemiology of HIV/AIDS.
153. US FDA: Approved and tentatively approved antiretrovirals in association with the president's emergency plan www.fda.gov/InternationalPrograms/ FDABeyondOurBordersForeignOffices/AsiaandAfrica/ucm119231.htm.
154. WHO: HIV drug resistance www.who.int/hiv/topics/drugresistance/hivresnet/ en/index.html ■ Summarizes the WHO's progress toward minimizing drug resistance.
155. The London Centre for Nanotechnology www.london-nano.com/